INFLIXIMAB
Description: INFLIXIMAB is a medication manufactured by FULFORD. It falls under the Uncategorised category and is available in injection form packed in 1 vial.
Active Ingredients
The active ingredient in INFLIXIMAB is infliximab.
Pharmacological Properties
INFLIXIMAB is a monoclonal antibody that works by targeting and neutralizing a specific protein in the body known as tumor necrosis factor-alpha (TNF-alpha). By inhibiting TNF-alpha, INFLIXIMAB helps reduce inflammation and modify the body’s immune response, making it effective in treating autoimmune conditions such as rheumatoid arthritis, Crohn’s disease, ulcerative colitis, psoriasis, and ankylosing spondylitis.
Indications
INFLIXIMAB is indicated for the treatment of various inflammatory and autoimmune conditions, including:
- Rheumatoid arthritis
- Crohn’s disease
- Ulcerative colitis
- Psoriasis
- Ankylosing spondylitis
Contraindications
INFLIXIMAB is contraindicated in individuals with a history of hypersensitivity reactions to infliximab or any of its components. It should not be used in patients with active infections or tuberculosis.
Dosage
The dosage of INFLIXIMAB varies depending on the condition being treated and the patient’s weight. It is typically administered intravenously at specific intervals as prescribed by a healthcare provider.
Side Effects
Common side effects of INFLIXIMAB may include:
- Headache
- Fatigue
- Nausea
- Injection site reactions
Severe side effects such as severe infections, infusion reactions, and worsening heart failure may also occur, and immediate medical attention should be sought if experienced.
Drug Interactions
INFLIXIMAB may interact with certain medications, including immunosuppressants, live vaccines, and other biologic agents. It is important to inform the healthcare provider of all medications being taken before starting INFLIXIMAB treatment.
Patient Counseling
Patients receiving INFLIXIMAB should be counseled on:
- The importance of regular follow-up appointments
- Monitoring for signs of infection
- Reporting any side effects or symptoms of concern
Clinical Evidence
Several clinical studies have demonstrated the efficacy and safety of INFLIXIMAB in the treatment of inflammatory and autoimmune conditions. Consult with a healthcare provider for more information on the specific clinical evidence supporting the use of INFLIXIMAB.
Frequently Asked Questions (FAQs)
Q: How often is INFLIXIMAB administered?
A: The frequency of INFLIXIMAB administration depends on the condition being treated and the patient’s response to the medication. It is typically administered at specific intervals, ranging from several weeks to several months.
Q: Can INFLIXIMAB be self-administered at home?
A: INFLIXIMAB should only be administered by healthcare professionals in a clinical setting due to the need for intravenous infusion and monitoring for potential side effects.
Q: What should I do if I miss a dose of INFLIXIMAB?
A: If a dose of INFLIXIMAB is missed, it is important to contact the healthcare provider to reschedule the appointment and receive the missed dose as soon as possible. Do not attempt to administer the medication on your own.
Q: Are there any dietary restrictions while taking INFLIXIMAB?
A: There are no specific dietary restrictions associated with INFLIXIMAB. However, it is essential to maintain a healthy and balanced diet as part of overall disease management and general well-being.
Q: Can pregnant women safely take INFLIXIMAB?
A: The use of INFLIXIMAB during pregnancy should be carefully considered and discussed with a healthcare provider, as it may pose risks to the developing fetus. Individual assessments and monitoring are necessary for pregnant women receiving INFLIXIMAB treatment.
